Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

@article{Kantarjian2002ImatinibMT,
  title={Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.},
  author={Hagop M Kantarjian and Susan M O'Brien and Jorge E. Cortes and Sergio A Giralt and Mary Beth Rios and Jianqin Shan and Francis J Giles and Deborah A. Thomas and Stefan H Faderl and Marcos de Lima and Guillermo Garcia-Manero and Richard Champlin and Ralph B. Arlinghaus and Moshe Talpaz},
  journal={Blood},
  year={2002},
  volume={100 5},
  pages={1590-5}
}
Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT) received imatinib mesylate (400-1000 mg/d). Disease was in chronic phase in 5 patients, accelerated in 15, and blastic in 8 (7 medullary, 1 extramedullary); median time from transplantation to relapse was 9 months (range, 1-137 months). Thirteen patients had undergone salvage donor lymphocyte infusion (DLI) (median time from DLI to imatinib mesylate therapy, 4 months… CONTINUE READING
67 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Gleevec (STI571) as therapy for relapse after bone marrow transplantation (BMT) [abstract

  • VA Moreira, DC Setubal, DG Albuquerque
  • Blood. 2001;98:264b
  • 2002

Gleevec/Glivec (imatinib mesylate, STI571) in patients with chronic myeloid leukemia

  • C Sawyers, A Hochhaus, E Feldman
  • Wassmann
  • 2002

Activity of an ABL specific tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis and other Philadelphia chromosome positive acute leukemias

  • BJ Druker, CL Sawyers, H Kantarjian
  • N Engl J Med
  • 2001

Clinical and laboratory evaluation of patients treated with STI571 (Gleevec) after allogeneic and syngeneic stem cell transplantation with relapsed Philadelphia chromosome-positive leukemia [abstract

  • AJ Ullmann, J Beck, K Koble
  • Blood
  • 2001

Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia

  • BJ Druker, M Talpaz, D Resta
  • N Engl J Med
  • 2001

Gleevec (formerly STI571): an active drug in patients with Ph chronic myeloid leukemia in accelerated phase—updated results of a phase II study [abstract

  • M Talpaz, RT Silver, B Druker
  • 2001

Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogeneic stem cell transplantation

  • B Wassman, H Pfeifer, U Scheuring
  • Blood [abstract]
  • 2001

Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation [abstract

  • RJ Soiffer, I Galinsky, D DeAngelo
  • Blood
  • 2001

Similar Papers

Loading similar papers…